ARAMCO-DIGITAL
15.1.2024 14:33:31 CET | Business Wire | Press release
Aramco Digital and Intel announced their intent to establish Saudi Arabia’s inaugural Open RAN (Radio Access Network) Development Center. The facility is expected to drive innovation, foster technological advancements and contribute to the digital transformation landscape in the Kingdom.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240115542031/en/
The collaborative effort aims to accelerate the development and deployment of Open RAN technologies, helping to enable the Kingdom to build robust and agile telecommunication infrastructure focused on accelerating digitization across industries. This collaboration aims to align with Saudi Arabia's Vision 2030, which focuses on technological advancements and economic diversification.
Open RAN, an evolving paradigm in wireless network architecture, allows for greater flexibility, interoperability and innovation. Aramco Digital brings a deep understanding of the development needs and ambitions of the Kingdom and the opportunities for Open RAN technology deployment, along with a unique perspective of the Kingdom's economic landscape. Intel, a pioneer in computing and communication technologies, brings its expertise in Open RAN technologies to the collaboration.
Highlights of the collaboration:
1. **Innovation Hub:** The Open RAN Development Center aims to serve as an innovation hub, fostering collaboration between Aramco Digital and Intel engineers, researchers and industry experts.
2. **Local Talent Development:** The Center aims to contribute to the development of local talent by providing training and hands-on experience in the rapidly evolving field of Open RAN and Edge computing technology.
3. **Economic Impact:** The collaboration aims to contribute to the local economy through technology-driven initiatives, aligning with the broader objectives of Vision 2030.
4. **Global Collaboration:** The collaboration on Open RAN between Aramco Digital and Intel is expected to extend beyond borders, connecting Saudi Arabia to the global landscape of Open RAN and Edge development and deployment.
Aramco Digital's CEO Tareq Amin said: "This collaboration is a testament to our commitment to helping drive innovation in the Kingdom. The Open RAN Development Center is expected to be a catalyst for digital evolution, providing a platform for collaboration, skill development and the creation of a vibrant technology ecosystem. At the heart of this collaboration is the creation of a vibrant pool of local capabilities for advanced 5G and future 6G technologies.”
"We are pleased to collaborate on Open RAN with Aramco Digital and to combine Intel's technological prowess in network and edge computing and software with the local insights and industry leadership of Aramco Digital. Together, we aim to accelerate the deployment of edge-native Open RAN solutions in Saudi Arabia and beyond," said [Sachin Katti, Intel senior vice president and general manager of the Network and Edge Group].
The Open RAN Development Center is planned to commence operations in 2024, marking a milestone in Saudi Arabia's journey towards a technology-driven future.
About Aramco Digital:
Aramco Digital is the digital and technology subsidiary of Aramco, a global integrated energy and chemicals company. Aramco Digital aims to help drive digital transformation and technological innovation across various sectors.
About Intel:
Intel (NASDAQ: INTC) is a world leader in computing innovation. The company designs and builds the essential technologies that serve as the foundation for the world's computing devices.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240115542031/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom